Table 4 Minimal sclerosis in BRCA1, BRCA2, and PALB2 mutation-associated tumours and in non-carriers of high-risk mutations
From: Tumour morphology predicts PALB2 germline mutation status
Minimal sclerosis | ||||
|---|---|---|---|---|
Present N (%) | Absent N (%) | Odds ratio (95% CI) | P -value | |
Non-carriers | 30 (3.9) | 734 (95.3) | ||
PALB2 mutation carriers | 14 (50) | 14 (50) | PALB2 vs non-carriers | |
19.7 (6–64.6) | 5 × 10−7 | |||
BRCA1 mutation carriers | 9 (22.5) | 31 (77.5) | BRCA1 vs non-carriers | |
3.15 (1.3–7.7) | 0.01 | |||
BRCA2 mutation carriers | 2 (11.1) | 16 (88.9) | BRCA2 vs non-carriers | |
1.29 (0.27–6.17) | 0.8 | |||
